Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group S.p.A. reported financial results for Q1 2024, with revenue decreasing by 1% to €236.0 million. The company adjusted its fiscal year 2024 guidance due to industry destocking and postponed orders, expecting revenue between €1,125 million to €1,155 million. Despite challenges, the company remains confident in its strong fundamentals and growth potential in biologics. The BDS segment revenue grew by 2% to €198.9 million, while the Engineering segment revenue decreased by 13% to €37.1 million. The company raised net proceeds of €170.5 million in a public offering, maintaining mid-term targets for fiscal years 2025 to 2027.
Stevanato Group, a global leader in drug containment, drug delivery, and diagnostic solutions, will participate in the Bank of America Securities Healthcare Conference from May 14 to May 16, 2024. The Company will present on May 15, 2024, at 11:20 a.m. (PT). A live webcast will be accessible on the Company's website, with a replay available for 90 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.